Use of prime editing in correcting mutations in cdkl5
AssigneesThe Broad Institute, Inc., President and Fellows of Harvard College
InventorsDavid R. Liu, KeIcee Everette
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods of using a prime editor in combination with prime editing guide RNAs (pegRNAs) and, optionally, nicking gRNAs to carry out prime editing to directly correct mutations (i.e., c.1412delA) in the CDKL5 gene that cause CDKL5 deficiency disorder. The present disclosure also provides compositions, complexes, and systems comprising the pegRNAs, nicking gRNAs, and/or prime editors disclosed herein, as well as polynucleotides and vectors encoding the same, and cells, kits, and pharmaceutical compositions comprising the same.
Claims92
A method of correcting a 1412delA mutation in a CDKL5 gene by prime editing comprising contacting a target DNA sequence comprising the CDKL5 gene with a prime editor and a prime editing guide RNA (pegRNA), wherein the pegRNA comprises a spacer sequence of GCCGGGAGGACTGGGGAATGG (SEQ ID NO:
- 1), GCCAGATCTCAGCAGAACAGG (SEQ ID NO:
- 2), GCATTCATGGAAAGCTCCCAG (SEQ ID NO:
- 3), GCCAGAGCAAAGCTGGGACCC (SEQ ID NO:
- 4), GCAGAGTCGGCATAGCTATAT (SEQ ID NO:
- 5), or TAGCTATGCCGACT (SEQ ID NO:
- 6), or a spacer sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to GCCGGGAGGACTGGGGAATGG (SEQ ID NO:
- 1), GCCAGATCTCAGCAGAACAGG (SEQ ID NO:
- 2), GCATTCATGGAAAGCTCCCAG (SEQ ID NO:
- 3), GCCAGAGCAAAGCTGGGACCC (SEQ ID NO:
- 4), GCAGAGTCGGCATAGCTATAT (SEQ ID NO:
- 5), or TAGCTATGCCGACT (SEQ ID NO:
- 6), or a spacer sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to GCCGGGAGGACTGGGGAATGG (SEQ ID NO:
- 1), GCCAGATCTCAGCAGAACAGG (SEQ ID NO:
- 2), GCATTCATGGAAAGCTCCCAG (SEQ ID NO:
- 3), GCCAGAGCAAAGCTGGGACCC (SEQ ID NO:
- 4), GCAGAGTCGGCATAGCTATAT (SEQ ID NO:
- 5) or TAGCTATGCCGACT (SEQ ID NO:
- 6).
A prime editing guide RNA (pegRNA) comprising a spacer sequence of GCCGGGAGGACTGGGGAATGG (SEQ ID NO:
- 1), GCCAGATCTCAGCAGAACAGG (SEQ ID NO:
- 2), GCATTCATGGAAAGCTCCCAG (SEQ ID NO:
- 3), GCCAGAGCAAAGCTGGGACCC (SEQ ID NO:
- 4), GCAGAGTCGGCATAGCTATAT (SEQ ID NO:
- 5), or TAGCTATGCCGACT (SEQ ID NO:
- 6), or a spacer sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to GCCGGGAGGACTGGGGAATGG (SEQ ID NO:
- 1), GCCAGATCTCAGCAGAACAGG (SEQ ID NO:
- 2), GCATTCATGGAAAGCTCCCAG (SEQ ID NO:
- 3), GCCAGAGCAAAGCTGGGACCC (SEQ ID NO:
- 4), GCAGAGTCGGCATAGCTATAT (SEQ ID NO:
- 5), or TAGCTATGCCGACT (SEQ ID NO:
- 6), or a spacer sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to GCCGGGAGGACTGGGGAATGG (SEQ ID NO:
- 1), GCCAGATCTCAGCAGAACAGG (SEQ ID NO:
- 2), GCATTCATGGAAAGCTCCCAG (SEQ ID NO:
- 3), GCCAGAGCAAAGCTGGGACCC (SEQ ID NO:
- 4), GCAGAGTCGGCATAGCTATAT (SEQ ID NO:
- 5), TAGCTATGCCGACT (SEQ ID NO:
- 6).
A system comprising a pegRNA of Table 1 or Table 2, an ngRNA of Table 3, and a prime editor.
A method of correcting a 1412delA mutation in a CDKL5 gene by prime editing comprising contacting a target DNA sequence comprising the CDKL5 gene with a prime editor and a prime editing guide RNA (pegRNA), wherein the pegRNA comprises a reverse transcription template (RTT) of the sequence of any one of SEQ ID NOs:
- 404-563, or a RTT at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the sequence of any one of SEQ ID NOs:
- 404-563, or a RTT comprising one, two, three, four, or five mutations, insertions, or deletions relative to the sequence of any one of SEQ ID NOs:
- 404-563.
A prime editing guide RNA (pegRNA) comprising a reverse transcription template (RTT) of the sequence of any one of SEQ ID NOs:
- 404-563, or a RTT at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the sequence of any one of SEQ ID NOs:
- 404-563, or a RTT comprising one, two, three, four, or five mutations, insertions, or deletions relative to the sequence of any one of SEQ ID NOs:
- 404-563.
A method of correcting a c.826-1 G-to-A point mutation in a CDKL5 gene by prime editing comprising contacting a target DNA sequence comprising the CDKL5 gene with a prime editor and a prime editing guide RNA (pegRNA), wherein the pegRNA comprises a spacer sequence of GCTGTCAAGTATCTGTCAGCT (SEQ ID NO:
- 7), or a spacer sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to GCTGTCAAGTATCTGTCAGCT (SEQ ID NO:
- 7), or a spacer sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to GCTGTCAAGTATCTGTCAGCT (SEQ ID NO:
- 7).
A pegRNA comprising a spacer sequence of GCTGTCAAGTATCTGTCAGCT (SEQ ID NO:
- 7), or a spacer sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to GCTGTCAAGTATCTGTCAGCT (SEQ ID NO:
- 7), or a spacer sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to GCTGTCAAGTATCTGTCAGCT (SEQ ID NO:
- 7).
A nicking guide RNA comprising the sequence GATTTCAAACCCAGAGACTTC (SEQ ID NO:
- 15), GTTCTGGATCGTTCTCCTTCA (SEQ ID NO:
- 16), or GTACTGAAGTTGGACCCAGCT (SEQ ID NO:
- 17), or a sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to GATTTCAAACCCAGAGACTTC (SEQ ID NO:
- 15), GTTCTGGATCGTTCTCCTTCA (SEQ ID NO:
- 16), or GTACTGAAGTTGGACCCAGCT (SEQ ID NO:
- 17), or a sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to GATTTCAAACCCAGAGACTTC (SEQ ID NO:
- 15), GTTCTGGATCGTTCTCCTTCA (SEQ ID NO:
- 16), or GTACTGAAGTTGGACCCAGCT (SEQ ID NO:
- 17).
A method of correcting a cluster of mutations in exon 8 of CDKL5 by prime editing comprising contacting a target DNA sequence comprising the CDKL5 gene with a prime editor and a prime editing guide RNA (pegRNA), wherein the pegRNA comprises a spacer sequence of CAGAGTACGTTGCCACCAGA, or a spacer sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to CAGAGTACGTTGCCACCAGA, or a spacer sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to CAGAGTACGTTGCCACCAGA.
A pegRNA comprising a spacer sequence of CAGAGTACGTTGCCACCAGA (SEQ ID NO:
- 8), or a spacer sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to CAGAGTACGTTGCCACCAGA (SEQ ID NO:
- 8), or a spacer sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to CAGAGTACGTTGCCACCAGA (SEQ ID NO:
- 8).
A nicking guide RNA comprising the sequence GTGGAAATGTCATTCTATTTT (SEQ ID NO:
- 18), or a sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to GTGGAAATGTCATTCTATTTT (SEQ ID NO:
- 18), or a sequence comprising one, two, three, four, or five mutations, insertions, or deletions relative to GTGGAAATGTCATTCTATTTT (SEQ ID NO:
- 18).
A method for treating CDKL5 deficiency disorder (CDD) by prime editing comprising contacting a target DNA sequence comprising a CDKL5 gene comprising a pathogenic mutation with a prime editor, or a nucleotide sequence encoding a prime editor, and a pegRNA, or a nucleotide sequence encoding a prime editor, wherein the prime editor comprises an amino acid sequence of any one of SEQ ID NOs:
- 355-357, or an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to an amino acid sequence of any one of SEQ ID NOs:
- 355-357.
Dependencies are inferred from the claim text.